Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Neoplasms 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Prostatic Neoplasms 4Breast Neoplasms 4Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Head and Neck Neoplasms 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Neuroblastoma 1Nephrotic Syndrome 1Neoplasms, Plasma Cell 1NSCLC 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 409Methotrexate 246Cytarabine 231Vincristine 188fludarabine phosphate 172Dexamethasone 169fludarabine 143Etoposide 143Peripheral Blood Stem Cell Transplantation 136Filgrastim 132Whole-Body Irradiation 116Mycophenolic Acid 115Busulfan 112Doxorubicin 109Tacrolimus 106Mercaptopurine 105Cyclosporine 95Radiotherapy 93Melphalan 93Rituximab 90pegaspargase 88Prednisone 84Asparaginase 84Daunorubicin 82Granulocyte Colony-Stimulating Factor 74blinatumomab 72Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Pharmaceutical Preparations × Clear all
NCT03076437 2021-03-19

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Shenzhen Institute for Innovation and Translational Medicine

Phase 1/2 Completed
28 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03191773 2017-06-20

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Second Affiliated Hospital of Guangzhou Medical University

Phase 1/2 Unknown
100 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡